ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Aktis Oncology Announces $175 Million Series B Financing

NextEdge Admin

30 Sep 2024

1 min 58 sec

Aktis Oncology, a clinical-stage biotech company developing targeted alpha radiopharmaceuticals for solid tumors, announced the successful closure of an oversubscribed $175 million Series B financing. The round was led by RA Capital Management, with co-leads RTW Investments and Janus Henderson Investors. Other investors included T. Rowe Price Associates, Avidity Partners, and a life sciences-focused investment fund. Existing strategic investors Bristol Myers Squibb, Eli Lilly, and MRL Ventures Fund also participated.

Aktis will present three abstracts, including one oral presentation, at the EORTC-NCI-AACR Symposium in Barcelona, Spain, in October 2024. This includes AKY-1189, their lead miniprotein alpha radioconjugate targeting Nectin-4, under development for multiple tumor types.

Matthew Roden, PhD, CEO of Aktis Oncology, highlighted investor confidence in the company’s platform, pipeline, and supply chain, noting they are well-capitalized with over $300 million to advance treatments for new patient populations.

In addition, Andrew Levin, MD, PhD, from RA Capital, will join Aktis’ Board of Directors, while Lauren Lee, PhD, from RTW Investments, and Vish Sridharan, MD, from Janus Henderson Investors, will join as Board Observers.

Levin praised Aktis' unique technology, experienced team, and strong pipeline, emphasizing the potential of their radiopharmaceuticals to offer new treatment options for cancer patients.